FCGRT and autoimmune bullous skin disease: The rationale for FcRn inhibition in diseases with a clearly different pathogenesis (i.e., pemphigoid versus pemphigus) is based on the finding that the (different) autoantibodies reach their target antigen through the bloodstream, where the half‐life is controlled by the FcRn.